Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $7.87 USD
Change Today +0.24 / 3.15%
Volume 47.3K
As of 8:04 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

medgenics inc (MDGN) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/13/15 - $9.63
52 Week Low
12/4/14 - $3.68
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MEDGENICS INC (MDGN)

Related News

No related news articles were found.

medgenics inc (MDGN) Related Businessweek News

No Related Businessweek News Found

medgenics inc (MDGN) Details

Medgenics, Inc., a clinical stage medical technology company, engages in the research and development of products in the field of biotechnology and associated medical equipment in the United States. It develops transduced autologous restorative gene therapy, TARGT platform to provide protein and peptide therapies to treat a range of chronic diseases and conditions. The company’s lead product candidate is MDGN-201, which is in the Phase I/II clinical trials for the treatment of end stage renal disease. Medgenics, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.

40 Employees
Last Reported Date: 02/13/15
Founded in 2000

medgenics inc (MDGN) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $765.0K
Chief Financial Officer
Total Annual Compensation: $565.0K
Chief Legal Officer
Total Annual Compensation: $154.0K
Chief Scientific Officer
Total Annual Compensation: $660.0K
Compensation as of Fiscal Year 2014.

medgenics inc (MDGN) Key Developments

Medgenics, Inc.(AMEX:MDGN) added to Russell 2000 Index

Medgenics, Inc. will be added to Russell 2000 Index

Medgenics, Inc.(AMEX:MDGN) added to Russell 3000 Index

Medgenics, Inc. will be added to the Russell 3000 Index.

Medgenics, Inc. Announces Board Appointments

On June 9, 2015, the Board of Directors of Medgenics, Inc., elected Barbara G. Duncan to fill one of its vacant directorships, effective July 22, 2015. In connection with Ms. Duncan's election as a Director, the Compensation Committee of the Company's Board of Directors recommended. In addition, as of June 9, 2015, the Company and Ms. Duncan entered into a non-executive director appointment letter agreement setting forth, among other things, Ms. Duncan's duties as a director. Pursuant to the agreement, Ms. Duncan will be entitled to the same cash fees for her services as a director as the other non-executive directors of the Company. Ms. Duncan also agreed to maintain the confidentiality of all confidential business information, to disclose conflicts of interest to the Company and not to compete or solicit certain employees or other parties with which the Company does business for a period ending twelve months following the termination of her directorship.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MDGN:US $7.87 USD +0.24

MDGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MDGN.
View Industry Companies

Industry Analysis


Industry Average

Valuation MDGN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 9.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDGENICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at